Highest-materiality recent filing
Allurion completes 1-for-15 reverse stock split to support NYSE relisting
Reverse split effective June 18, 2026; outstanding shares reduced from ~15M to ~1,000,417.
Allurion Technologies dismisses Deloitte & Touche, appoints CBIZ; discloses material weaknesses
Deloitte & Touche LLP dismissed as independent auditor effective May 22, 2026; Audit Committee approved.
NYSE notified Allurion on March 6, 2026 of delisting for failing to maintain $15M average global market cap over 30 consecutive days.
NYSE notified Allurion it fails Section 802.01B: requires ≥$50M stockholders' equity or ≥$50M market cap on 30-day average.
Allurion warrant inducement: $3M gross proceeds, exercise price cut to $1.15
Exercising holders purchase 2,659,565 shares at $1.15; Company expects $3.0M gross proceeds.
FDA grants PMA approval for Allurion gastric balloon system for obesity
Allurion Smart Capsule approved for adults 22-65 with BMI 30-40 kg/m² after unsuccessful weight loss attempt.
Allurion Q4 revenue up 22-37% QoQ; FY2025 revenue ~$15M
Q4 2025 revenue $3.3-3.7M (22-37% QoQ increase); full-year revenue ~$15M.
Re-elected directors Omar Ishrak, M.D., Douglas Hudson, and R. Jason Richey to serve until 2028 annual meeting.
Allurion becomes debt-free via preferred equity exchange, raises $5M, Q3 revenue falls 50%
Exchanged all Notes and RIFA debt for Series B convertible preferred stock with $1,000 stated value, 8.25% dividend; company becomes debt-free.
Allurion restates financials for 2023-2024 and Q1 2025 due to fair-value accounting errors
Non-reliance on prior financial statements for annual periods 2023-2024 and Q1 2025 due to RIFA and Notes fair value errors.
Allurion Q2 revenue plunges to $3.4M; restructure, potential restatement of non-cash items
Q2 2025 revenue $3.4M, down 71% YoY from $11.8M; gross margin 74% vs 76%.
Allurion cuts ~65% workforce, reports preliminary Q2 revenue ~$3M, shifts to GLP-1 combo therapy
Preliminary Q2 2025 revenue ~$3M, operating loss ~$7M, improved from $9.3M loss in Q2 2024; operating expenses down ~50% YoY.
Allurion Q1 revenue $5.6M, net operating loss narrows 36% YoY; maintains FY 2025 guide
Q1 revenue of $5.6M (down 40% YoY); gross margin expanded to 75% from 73% YoY.
Allurion amends notes; $5M converted at $3.35 as market cap falls below $15M
Second Amendment to Note Purchase Agreement with RTW Investments added conversion provisions triggered by sub-$15M market cap.
Allurion Q4 revenue $5.6M, down 32% YoY; guides 2025 rev ~$30M, 50% opex cut
Q4 revenue $5.6M (down 32% YoY); full-year $32.1M; 2025 guidance ~$30M.
Issued 900,000 shares of common stock at $5.23/share and 1,800,000 warrants (exercise $5.23, 5-year term, exercisable only after stockholder approval).
Gross proceeds of approximately $7.5 million from sale of 1,240,000 shares at $6.00 per share with accompanying warrants.
Allurion raises $2.5M via private placement; prelim Q4 rev $5.6M, FY rev ~$32M
Private placement of 841,751 shares at $2.97/share for gross proceeds of $2.5M; option for additional $10M.
Omnibus Amendment imposes minimum cash balances and minimum trailing 12-month revenue tested quarterly starting Q3 2025.
Allurion shareholders approve reverse stock split and share issuances at 2024 annual meeting
Class I directors re-elected: Shantanu Gaur, Krishna Gupta, Nicholas Lewin; votes for ranged 27.2M-33.7M.
Allurion Q3 revenue $5.4M, down 70% YoY; FY2024 guidance cut to $30-35M
Revenue $5.4M vs $18.2M prior year, includes $1.2M France recall charge; gross margin fell to 58% from 77%.
Allurion receives NYSE notice for market cap non-compliance; stock to trade with ".BC"
NYSE notified Allurion avg market cap <$50M over 30 days ended Aug 29, 2024 and equity <$50M.
Allurion receives NYSE deficiency notice for average stock price below $1.00
30-day average closing price below $1.00 as of Aug 8, 2024 triggered NYSE non-compliance notice.
Q2 2024 revenue $11.8M, up 25% sequentially from Q1 but down from $13M in Q2 2023.
Allurion Balloon sales suspended in France; device withdrawn pending remediation plan
French regulator ANSM suspended sales; Allurion withdrawing device from French market.
Allurion prices $20M public offering and $2.7M private placement with RTW
Public offering of 14.4M shares + warrants at $1.20/share for $17.3M gross; underwriters have 30-day option for 15% more.
Allurion Q1 revenue $9.4M, down 33% YoY but up 14% sequentially; guides FY revenue $60-65M
Revenue $9.4M, down from $14.1M YoY due to macroeconomic headwinds; procedural volume up 12% YoY and 22% sequentially.
Allurion preliminary Q1 revenue $9.2-9.3M (+12-13% QoQ); cash burn slashed to $8-9M
Revenue range $9.2-9.3M, up 12-13% vs Q4 2023.
Allurion closes $48M convertible note deal with RTW; repays Fortress loan, extends cash runway
Issued $48M convertible senior secured notes to RTW to fully repay existing Fortress term loan.
Allurion Q4 2023 revenue drops to $8.2M from $19.2M; operating loss widens to $25.7M
Q4 2023 revenue $8.2M (down 57% YoY); full year 2023 revenue $53.5M.
Allurion prelim 2023 rev $53-54M, cuts 30% staff, 2024 outlook $60-65M
Full-year 2023 revenue expected $53-54M; gross margin 77-78%; procedural volume up 30% YoY.
Allurion Technologies Amends Credit Facility, Prepaids $20M and Secures Covenant Relief
Waived December 31, 2023 minimum revenue covenant test under existing credit agreement with Fortress Credit Corp.
Allurion enters up to $100M equity facility with Chardan; issues 35,511 commitment shares
Entered ChEF Purchase Agreement with Chardan for up to $100M in common stock sales over 36 months.
Chief Commercial Officer Benoit Chardon resigned effective December 31, 2023.
Allurion Q3 revenue $18.2M (+13% YoY), loss $26.2M; completes AUDACITY trial enrollment
Revenue $18.2M, up 13% YoY and 40% sequentially from Q2 2023; gross profit 77%.
On June 24, 2026, R. Jason Richey, a Class II member of the board of directors (the “Board”) of Allurion Technologies, Inc. (the “Company”), notified the Company of his resignation from the Board and his role as the chairperson of the Audit Committee of the Board (the “Audit Committee”), effective the same day.
appointed R. Jason Richey to the Board as a Class II director
Shantanu Gaur, Chief Executive Officer of the Company, will serve as the Company’s principal financial officer and principal accounting officer, effective as of the close of business on November 13, 2024, until a replacement for Mr. Geberth is found.
Christopher Geberth, Chief Financial Officer of Allurion Technologies, Inc. (the “Company”), notified the Company of his decision to resign, effective as of the close of business on November 13, 2024, to pursue other interests.
On September 2, 2024, the Board of Directors (the "Board") of Allurion Technologies, Inc. ("Allurion" or the "Company") appointed Keith Johns to the Board as a Class III director to fill a vacancy created by an increase in the size of the Board from seven members to eight members, effective September 2, 2024.
appointed Milena Alberti-Perez to the Board as a Class III director to fill the vacancy on the Board, effective immediately.
On December 12, 2023, the Company's Chief Commercial Officer, Benoit Chardon, resigned effective December 31, 2023.
Effective upon the closing of the Business Combination, Allurion entered into a new employment agreement with Mr. Geberth, pursuant to which Allurion will continue to employ Mr. Geberth as Chief Financial Officer on an “at will” basis.
Effective upon the closing of the Business Combination, Allurion entered into a new employment agreement with Dr. Gaur, pursuant to which Allurion will continue to employ Dr. Gaur as Chief Executive Officer on an “at will” basis.
Max materiality 0.85 · Median 0.70 · Most common event other_material